0841 GMT July 17, 2019
This novel approach centers around the research team's previous discovery that TMAO — trimethylamine N-oxide, a byproduct formed in the gut during digestion of animal fats — is linked to atherosclerosis and heart disease. Now, the team has identified a naturally occurring inhibitor called DMB — 3,3-dimethyl-1-butanol, found in some cold-pressed extra virgin olive oils and grape seed oils — that reduced levels of TMAO and reduced atherosclerosis in mice, Medical Xpress reported.
This discovery may represent a potential new therapeutic approach for the prevention of heart disease, the number one killer in the United States, as well as other metabolic diseases linked to gut microbes, such as diabetes.
The link between TMAO, gut microbes and heart disease was first discovered four years ago by the same investigative team, led by Stanley Hazen, PhD, Chair of the Department of Cellular and Molecular Medicine in the Lerner Research Institute.
"Many chronic diseases like atherosclerosis, obesity and diabetes are linked to gut microbes," said Hazen. "These studies demonstrate the exciting possibility that we can prevent or retard the progression of diet-induced heart diseases starting in the gut. This opens the door in the future for new types of therapies for atherosclerosis, as well as other metabolic diseases."
TMAO is a gut metabolite formed during the digestion of the nutrients choline, phosphatidylcholine (lecithin) and carnitine, which are abundant in animal products. Blood TMAO levels are associated with heightened risk of heart attacks, stroke and death in clinical studies. Carnitine is abundant in red meat and liver, while choline and lecithin are abundant in beef, lamb, liver, egg yolk and high-fat dairy products.
The present study suggests that targeted inhibition of the first step in TMAO generation, commensal microbial trimethylamine (TMA) production, can help to prevent diet-induced atherosclerosis. The research team inhibited TMA production using 3,3-dimethyl-1-butanol (DMB) in mice fed a high choline or carnitine diet. The mice treated with the inhibitor had less TMAO and developed less atherosclerosis. DMB is not an antibiotic. This important fact suggests that a treatment could target a specific microbial pathway while protecting the gut flora and avoiding antibiotic overuse and resistance, which is a worldwide health crisis.